Midterm results of low-dose intravitreal triamcinolone as adjunctive treatment for proliferative vitreoretinopathy.
To evaluate the midterm anatomical and functional outcomes of intravitreal injection of low-dose triamcinolone acetonide in silicone oil-filled eyes as an adjunctive treatment for proliferative vitreoretinopathy. This is a retrospective interventional case series. Patients with proliferative vitreoretinopathy grade C or D received pars plana vitrectomy combined with silicone oil tamponade and intravitreal injection of 2 mg of triamcinolone acetonide in the first stage and silicone oil removal in the second stage. Primary outcome measures were retinal reattachment rate and best-corrected visual acuity. In all, 37 eyes from 37 patients were included in this study. The mean follow-up duration was 22.9 ± 9.6 months. Retina was reattached in 36 (97.3%) eyes at the last visit. The mean best-corrected visual acuity was 1.76 ± 0.56 logMAR at baseline, which improved to 0.87 ± 0.60 logMAR at the last visit (P < 0.001). Best-corrected visual acuity increased in 31 (83.8%) eyes, remained unchanged in 5 (13.5%) eyes, and decreased in 1 (2.7%) eye at last visit compared with baseline. Low-dose (2 mg) triamcinolone acetonide intravitreal injection as an adjunct to vitrectomy and silicone oil tamponade in treating proliferative vitreoretinopathy (grade C or D) appears to be effective and safe.